▶주메뉴 바로가기

▶본문 바로가기

THE INVESTOR
August 04, 2020
Big Reunion

Deals

Mirae Asset makes $22m earnings from BioNTech investment

  • PUBLISHED :April 16, 2020 - 16:09
  • UPDATED :April 16, 2020 - 16:09
  • 폰트작게
  • 폰트크게
  • facebook
  • twitter
  • sms
  • print

Mirae Asset Financial Group said on April 16 it has sold Nasdaq-listed German drugmaker BioNTech for $37 million, earning a hefty profit from its previous investment of $15 million.

The German company is known to hold one of the three mRNA-based substance that is currently a candidate for COVID-19 vaccines.

Three months after making its deal, the phara firm went to public on Nasdaq through the American Depository Receipt -- the way of making hard-to-trade foreign stocks available to investors in the United States.



After fulfilling safeguard deposit at the end of this month, Mirae Asset will realize nearly a 2.5 times of profit from its previous investment.

The BioNTech deal is the first retrieval from Mirae Asset-Naver Asia Growth Fund, which was launched in June 2018. Its overseas affiliate firms also invested together for the investment.

By Jie Ye-eun (yeeun@heraldcorp.com)

  • facebook
  • twitter
  • sms
  • print

EDITOR'S PICKS